Carina Biotech: Cellular immunotherapies for the treatment of cancer

We are an Australian biotech company researching and developing chimeric antigen receptor T cell (CAR-T) therapies to treat cancer. Headquartered in Adelaide, we have a network of research providers and collaborators including leading scientists at the University of South Australia, the Women’s & Children’s Hospital, the University of Adelaide and the Seattle Children’s Hospital in the United States.

Investment opportunity

Direct investment and licensing/partnership opportunities.

Gallery images

Investor information

Financial information

Investment sought: A$5M - A$25M


No documents provided.

Project status update


Project dependencies


Technology utilised

Carina Biotech is a global leader in next-generation CAR-T (chimeric antigen receptor T cell) technologies.

Project timelines

Expected start date

Expected end date

Funding round finish date

Website View all investment opportunities